TransMedics Group (TMDX) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1-year price objectives for TransMedics Group's stock. Their TMDX share price forecasts range from $74.00 to $110.00. On average, they expect the company's stock price to reach $85.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.

TransMedics Group's stock was trading at $61.72 at the beginning of the year. Since then, TMDX shares have decreased by 8.0% and is now trading at $56.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TMDX earnings forecast.

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.12. The company had revenue of $42.46 million for the quarter, compared to the consensus estimate of $42.42 million. TransMedics Group had a negative net margin of 11.77% and a negative trailing twelve-month return on equity of 9.98%. The firm's revenue was up 136.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.41) EPS.

ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), Innovator IBD 50 ETF (FFTY), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), BNY Mellon Innovators ETF (BKIV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC).

TransMedics Group updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $180.00 million-$190.00 million, compared to the consensus revenue estimate of $173.91 million.

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $56.77.

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.85 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

The company employs 212 workers across the globe.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.